News

The director of the Joseph Epstein Center for Emergency Medicine Research discussed the complexities of diagnosing migraine in the emergency department and whether institutions should reevaluate their internal processes to do so. [WATCH TIME: 3 minutes]

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

The FDA has set a prescription drug user fee act goal date of September 28, 2022, for the investigational treatment from TG Therapeutics.

Chris Kalafatis, MD, MRCPsych, discussed a new tool, the Integrated Cognitive Assessment, developed by Cognetivity, and its potential for patients with dementias and multiple sclerosis.

The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]

Over a 10-year period, apomorphine sublingual film was projected to be dominant in 70% of patients compared with apomorphine hydrochloride injection and 71% vs levodopa inhalation powder.

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space.

Results from a recent study further suggest that using digital cognitive behavior therapy for insomnia, or dCBT-I, during pregnancy may be effective in preventing postpartum depression and anxiety.

Investigators used cross-sectional data from the observational population-based cohort of the Maastricht Study, calculating LIBRA scores with 12 dementia risk and protective factors.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]

Jessica Fesler, MD, MEd, staff epileptologist, Cleveland Clinic, offered insight on the future of seizure apps and how if improved, they could alter the treatment of patients with epilepsy.

The director of the Joseph Epstein Center for Emergency Medicine Research discussed the origin behind her multinational study evaluating the outcome of headache in emergency departments. [WATCH TIME: 3 minutes]

The newly adopted AASM guidelines are designed to help health care providers treating obstructive sleep apnea know when to discuss referral for upper airway or bariatric surgery evaluation with their patients.

The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.

Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.

The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Statistical significance was observed for both the MycarinG study’s primary and secondary end points in a population of 200 patients with myasthenia gravis treated with the UCB agent.

Those who demonstrated amyloid-ß positivity with clinical anxiety were at a statistically significant increased risk of incident mild cognitive impairment.

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the phase 2 open-label study of ganaxolone in TSC and whether drug development remains the top priority for these patients. [WATCH TIME: 3 minutes]

Kent Pryor, PhD, the CEO of ZZ Biotech, provided insight into a phase 2 trial that will evaluate the safety and efficacy of the investigational treatment in 16 patients with amyotrophic lateral sclerosis.

Results from the cohort study contrast with reports in multiple sclerosis, finding that new remission silent lesions were rare in both myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder.

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

The cohort study was conducted using data from the Danish Multiple Sclerosis Registry for women with clinically isolated syndrome and relapsing remitting multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 10, 2021.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute spoke on the latest advances with epilepsy surgery, as well as what still needs to be learned. [WATCH TIME: 5 minutes]

Leaders in the epilepsy space provided their thoughts on the most promising aspects, initial takeaways, and dominating conversations at the 2021 American Epilepsy Society annual meeting.

Adverse effects were common but manageable among patients and were not identified as a reason to discontinue treatment in those with refractory disease.

Investigators included 1059 patients from a population-based multidisciplinary Greek study aimed as estimating dementia epidemiology in the aging population.